| abstract |
Anti-AREG antibodies or immunoreactive fragments thereof are provided for the treatment, diagnosis or prophylaxis of fibrotic diseases including, but not limited to, renal fibrosis, liver fibrosis, lung fibrosis, particularly IPF. It further provides a polynucleotide or nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for making the antibody. The anti-AREG antibody specifically binds to AREG through a binding moiety located in the EGF-like domain and blocks the function of AREG. |